AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Macrophage colony-stimulating factor 1 receptor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P07333

UPID:

CSF1R_HUMAN

Alternative names:

CSF-1 receptor; Proto-oncogene c-Fms

Alternative UPACC:

P07333; B5A955; D3DQG2; Q6LDW5; Q6LDY4; Q86VW7

Background:

The Macrophage colony-stimulating factor 1 receptor (CSF-1R), also known as Proto-oncogene c-Fms, plays a pivotal role in the regulation of survival, proliferation, and differentiation of hematopoietic precursor cells. It is crucial for normal bone and tooth development, fertility, and immune responses, acting through pathways like ERK1/2, JNK, and AKT1.

Therapeutic significance:

CSF-1R's involvement in diseases such as Leukoencephalopathy, hereditary diffuse, with spheroids 1, and Brain abnormalities, neurodegeneration, and dysosteosclerosis, underscores its potential as a target for therapeutic intervention in neurodegenerative disorders and bone diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.